|
Daily Medical Update
Rhabdomyolysis
Thursday, July 30, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Cancer chemotherapy and pharmacology (2026) - Systematic Review
Key Findings
- Increased CK ranged from 3,070 to 47,000 U/L, with onset from 3 days to 48 months after CDK4/6 inhibitor-statin exposure or shortly after statin dose escalation.
- CK levels ranged from 3,070 to 47,000 U/L, AKI occurred in five cases, five patients recovered fully, one had persistent renal dysfunction, and mortality occurred in one case.
📋 Practice Implication: Medication reconciliation for patients on CDK4/6 inhibitors should specifically flag statins and recent statin dose escalation as triggers for urgent CK and renal assessment.
|
World journal of nephrology (2026) - Prospective Study
Key Findings
- AKI developed in 51.9% of 54 ICU patients with rhabdomyolysis.
- A McMahon score threshold of 4.75 predicted AKI with 78.6% sensitivity and 76.9% specificity, while initial LDH and bicarbonate were independently associated with AKI occurrence.
📋 Practice Implication: Early triage should combine CK with admission LDH, bicarbonate, and McMahon score rather than waiting for creatinine trends alone.
|
Frontiers in medicine (2026) - Case Report and Literature Review
Key Findings
- The reported patient had recurrent generalized pain and weakness after mild exertion with repeatedly increased CK and hypokalemia.
- Spontaneous, refractory hypokalemia from primary aldosteronism increased the risk of recurrent rhabdomyolysis until the endocrine cause was identified.
📋 Practice Implication: Recurrent or exertion-triggered rhabdomyolysis with hypokalemia should prompt evaluation for primary aldosteronism, especially when potassium depletion is spontaneous or refractory.
|
Postgraduate medical journal (2026) - Cohort Study
Key Findings
- Among 855 adults with CK above 1000 IU/L, AKI developed in 368 patients (43%) and renal replacement therapy was required in 43 patients (5.0%).
- CK levels above 5000 IU/L were associated with more severe AKI and greater dialysis requirement; among 269 AKI survivors followed at least three years, 87.4% fully recovered renal function.
📋 Practice Implication: CK above 5000 IU/L should raise the intensity of renal surveillance and fluid management, while prognosis counseling can note that most AKI survivors recover kidney function.
|
PloS one (2026) - Retrospective Cohort Study
Key Findings
- Hemoadsorption with CRRT was associated with significant myoglobin reductions at all measured time points compared with CRRT alone.
- Starting hemoadsorption within 12 hours was associated with shorter AKI duration, less acute kidney disease, and longer survival than late initiation (49.2 vs 15.3 days).
📋 Practice Implication: For severe ischemic/reperfusion rhabdomyolysis with AKI in the ICU, early nephrology and critical care escalation may affect the window for adjunctive hemoadsorption benefit.
|
|
💡
Summary
Recent rhabdomyolysis literature emphasizes early AKI risk stratification, medication-interaction vigilance, and rapid escalation for severe ICU presentations. The strongest current evidence links higher CK burden, admission metabolic markers, and early extracorporeal support timing with renal outcomes, while case-based data highlight preventable causes such as CDK4/6 inhibitor-statin combinations and primary aldosteronism-related hypokalemia.
|
|